Biofourmis is advancing drug development, clinical research, and Software as a Medical Device (SaMD) through the use of the latest artificial intelligence and machine learning technology across a spectrum of therapeutic areas.
Our customized, end-to-end solutions with our FDA-cleared analytics platform enable world-class care to patients and advanced insight to clinicians.
Our customized, end-to-end solutions with our FDA-cleared analytics platform enable world-class care to patients and advanced insight to clinicians.
Delivery of care from anywhere, powered by the Biovitals analytics engine. The Biovitals FDA-cleared software utilizes AI and machine-learning to deliver meaningful notifications and unique insights to care teams.
Around the world and across multiple collaborations and studies, Biofourmis is helping clinical teams see patients like never before.
BioVitalsHF Treatment Algorithms
Circulation, AHA Journal
Remote Monitoring with Biosensors and AI
Annals of Internal Medicine
BioVitals A Personalized Physiology Analytics
IEEE Explore
RhythmAnalytics – Deep Learning for Arrhythmia Detection arXive.org – Cornell University
This study demonstrated the capability of our FDA-cleared RhythmAnalytics platform to detect >15 types of cardiac arrhythmias using continuous ECG recordings. The overall performance of RhythmAnalytics outperformed a panel of cardiologists and other industry-leading detection models.
The Boston Business Journal announces 2021 40 Under 40, an award that celebrates the city’s best and brightest young professionals each year.
